Epkinly: Dosage Form, Projected Sales, NCE-1 Date | Epcoritamab-Bysp

Epkinly

Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Epcoritamab-Bysp
Innovator :

GENMAB AND ABBVIE
Approval Date :

19-May-23
Data Exclusivity Expiry :

19-May-27
Market Exclusivity Expiry :

19-May-35
Dosage Form :

Injection
Strength :

4 mg/0.8 mL and 48 mg/0.8 mL
Therapeutic Category :

Anticancer
Revenue ($M) :

399

Year-wise Projected Sales ($M) :

2025 :

734
2026 :

1,236
2027 :

1,971
2028 :

2,608
2029 :

3,190
2030 :

3,668
2031 :

4,080

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Epkinly

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?